title: [Treatment of progressive multiple sclerosis with monthly pulsed cyclophosphamide-methylprednisolone: predictive factors of treatment response].
abstract: BACKGROUND
  Cyclophospamide is used in the treatment of progressive multiple sclerosis. We were looking for predictive indicators of treatment response.
  
  
  METHODS
  Forty-seven patients with secondary progressive multiple sclerosis and seven others with primary progressive received monthly infusions of cyclophosphamide (750mg/m2) and methylprednisolone (500mg). During the year before cyclophosphamide the EDSS had worsened one point in all patients with or without surimposed relapses. Evaluation was based on EDSS change at 6, 12, 24 months and 5 years.
  
  
  RESULTS
  Among secondary progressive patients, 91 per 100 (43/47) were stable or improved at 12 months, 65 per 100 (26/40) at 24 months and 22 per 100 (5/23) at 5 years. Annual relapse rate decreased from 0.81 before treatment to 0.48 during treatment and 0.12 after treatment (p<0.001). At 24 months, efficacy was correlated to a progressive phase lasting less than 5 years (p<0.01) and to a rapid increase of EDSS of at least 2 points the year before treatment (p<0.05). There were no influences of age, EDSS and surimposed relapses at the beginning of treatment, and other immunoactive drugs administrated before cyclophosphamide. There was no significant difference in quality of response to treatment between patients with primary progressive and secondary progressive multiple sclerosis.
  
  
  CONCLUSIONS
  Cyclophosphamide appears to be more efficient in early stage of progressive multiple sclerosis independently of age, relapses or neurological disability scale.
authors.affiliation: Service de Neurologie, CHU de Nice.
authors.forename: E
authors.initials: E
authors.lastname: Delmont
authors.forename: S
authors.initials: S
authors.lastname: Chanalet
authors.forename: V
authors.initials: V
authors.lastname: Bourg
authors.forename: M-H
authors.initials: MH
authors.lastname: Soriani
authors.forename: M
authors.initials: M
authors.lastname: Chatel
authors.forename: C
authors.initials: C
authors.lastname: Lebrun
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D001921:Brain / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D003710:Demography; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016899:Interferon-beta / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy* / Q000473:pathology; D011446:Prospective Studies; D020551:Pulse Therapy, Drug / Q000379:methods; D012008:Recurrence; D012189:Retrospective Studies
chemical_list: D000276:Adjuvants, Immunologic; D007166:Immunosuppressive Agents; D016899:Interferon-beta; D003520:Cyclophosphamide; D001379:Azathioprine; D008775:Methylprednisolone